Akorn signs commercial manufacturing supply agreement
Under the terms of the five-year agreement, Akorn will be responsible for the manufacturing and supply of the ophthalmic product. Revenues from this agreement are expected to begin
Anixa Biosciences has secured a patent from the Korean Ministry of Intellectual Property (MOIP) for its breast cancer vaccine technology.